The Bristol Myers Squibb subsidiary RayzeBio has opened a new 77,000-square-foot facility in Indianapolis, Indiana.

Bristol Myers Squibb has opened its radiopharmaceutical manufacturing facility in Indianapolis, which played a major role in ...

RayzeBio stock has fallen near its original IPO price, presenting an attractive buying opportunity. Click here to see why RYZB stock's valuation is reasonable.

RayzeBio’s IPO will support pivotal testing of a targeted radiopharmaceutical for cancer patients who progress after treatment with Novartis’s Lutathera. Neumora will apply its IPO cash toward ...

Bristol Myers Squibb is preparing to ship a new and possibly life-changing cancer treatment to patients across the world. The ...

RayzeBio is a recent IPO and a late-stage developer of radiotherapeutic product candidates targeting various cancers. Find out my analysis of RYZB stock.

Radiopharmaceutical drugmaker RayzeBio drew interest from two other large drugmakers before agreeing to a $4.1 billion buyout by Bristol Myers Squibb, newly published documents show.

SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- RayzeBio, Inc. (Nasdaq: RYZB), a targeted radiopharmaceutical company developing an innovative pipeline against validated solid tumor targets, today ...

RayzeBio's $4.1 billion deal to be acquired by Bristol Myers caps a brief but lucrative run as a public company for the radiopharmaceutical firm. RayzeBio went public in September at $18 a share ...

After leading his previous company through a back-to-back IPO and M&A deal, the former chief executive of RayzeBio has raised $370 million to develop ...

Three biotech VC veterans, including one of the co-founders of radiopharma success story RayzeBio, are launching a new investment fund called Scion Life Sciences.